AHR and neoplasm: We tested this possibility by analyzing the mutation loads of LUADs, LUSCs, and other cancers such as esophageal carcinomas (ESCAs) and stomach adenocarcinomas (STADs) in TCGA datasets, and reported that while LUADs, LUSCs, and STADs had more mutations/tumor than ESCAs (supplementary Fig. 2a), AhR expression levels in ESCAs were higher than LUADs, LUSCs, and STADs (supplementary Fig. 2b).